The US Food and Drug Administration (FDA) has granted tentative approval for Viatris’ new drug application of a single-tablet regimen to treat HIV-1 infection in the paediatric population.
The once-a-day tablet for oral suspension comprises a fixed-dose combination of 60mg abacavir, 5mg dolutegravir and 30mg lamivudine.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Viatris noted that the therapy is indicated for use in children weighing a minimum of 6kg to less than 25kg and has a strawberry flavour.
The recommended dose of the treatment is weight proportionate and is not intended for usage in patients with a previous hypersensitivity reaction to abacavir as well as in individuals who are HLAB*5701-positive.
This tentative approval will aid in making submissions to regulatory authorities, manufacturing and supply of the new paediatric formulation in 123 low and middle-income countries.
Viatris has a licensing agreement in place with the Medicines Patent Pool for paediatric dolutegravir.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTo manufacture and supply HIV treatment, the company signed a development deal with ViiV Healthcare and the Clinton Health Access Initiative.
The combination treatment is currently recommended by the World Health Organization as a first-line treatment for paediatric HIV patients.
Viatris Emerging Asia and Access Markets India president Rakesh Bamzai said: “Over the years, we have continued to seek improvements to existing molecules to better meet patient needs – we have introduced novel heat-stable generic formulations, more convenient packaging options and paediatric therapies.
“The approval of this single-tablet regimen – the fixed-dose combination of abacavir 60mg/dolutegravir 5mg/lamivudine 30mg – will reduce the pill burden for children living with HIV.”
